Immunome
IMNM
202 hedge funds and large institutions have $2.5B invested in Immunome in 2026 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 77 increasing their positions, 60 reducing their positions, and 27 closing their positions.
270% more call options, than puts
Call options by funds: $7.72M | Put options by funds: $2.09M
28% more repeat investments, than reductions
Existing positions increased: 77 | Existing positions reduced: 60
19% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 27
1.1% more ownership
Funds ownership: 103.13% → 104.23% (+1.1%)
0% more funds holding
Funds holding: 202 → 202 (0)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
2% less capital invested
Capital invested by funds: $2.54B → $2.5B (-$43.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$70.9M |
| 2 |
MIM
MetLife Investment Management
Whippany,
New Jersey
|
+$17.2M |
| 3 |
BlackRock
New York
|
+$13.6M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$10.2M |
| 5 |
Goldman Sachs
New York
|
+$8.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JFG
Jefferies Financial Group
New York
|
-$25.4M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$23.2M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$21M |
| 4 |
JP Morgan Chase
New York
|
-$19.9M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$18.6M |
IMNM Hedge Fund Activity: Q2 2026 in Review
202 of the 8,298 institutional investors tracked by Wall St. Rank reported a position in Immunome (IMNM) for Q2 2026, worth a combined $2.5B — down 1.7% from $2.54B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new IMNM positions and 27 closed out — a net gain of 5 holders — while 77 added to existing stakes and 60 trimmed.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $70.9M. The largest seller was Jefferies Financial Group, exiting entirely with an estimated $25.4M sold.
- 202 institutional investors held Immunome (IMNM) as of Q2 2026, unchanged from Q1 2026.
- Funds reported $2.5B of Immunome stock for Q2 2026, down 1.7% quarter-over-quarter.
- 32 funds opened new Immunome positions in Q2 2026 and 27 closed out, a net change of +5 holders.
- The largest Immunome buyer in Q2 2026 was T. Rowe Price Investment Management, an estimated $70.9M added.
- The largest Immunome seller in Q2 2026 was Jefferies Financial Group, an estimated $25.4M sold.
Based on aggregated 13F filings for Q2 2026.